Volume 68, Issue 4, Pages (October 2015)

Slides:



Advertisements
Similar presentations
Charles J. Ryan, M.D., Matthew R. Smith, M.D., Ph.D., Johann S. de Bono, M.B., Ch.B., Ph.D., Arturo Molina, M.D., Christopher J. Logothetis, M.D., Paul.
Advertisements

Volume 69, Issue 5, Pages (May 2016)
Volume 60, Issue 5, Pages (November 2011)
European Urology Focus
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017  Silke Gillessen, Gerhardt.
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 27, Issue 4, Pages (December 2016)
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 70, Issue 6, Pages (December 2016)
Volume 69, Issue 5, Pages (May 2016)
Fred Saad  European Urology Supplements 
Volume 73, Issue 2, Pages (February 2018)
Volume 67, Issue 4, Pages (April 2015)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 66, Issue 4, Pages (October 2014)
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.
Volume 53, Issue 5, Pages (May 2008)
Volume 69, Issue 5, Pages (May 2016)
Volume 51, Issue 4, Pages (April 2007)
Volume 69, Issue 1, Pages (January 2016)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Volume 68, Issue 1, Pages (July 2015)
Volume 52, Issue 4, Pages (October 2007)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 71, Issue 2, Pages (February 2017)
Volume 72, Issue 5, Pages (November 2017)
Volume 68, Issue 1, Pages (July 2015)
Volume 65, Issue 5, Pages (May 2014)
Volume 74, Issue 1, Pages (July 2018)
Volume 70, Issue 4, Pages (October 2016)
Volume 66, Issue 3, Pages (September 2014)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Volume 70, Issue 4, Pages (October 2016)
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Volume 74, Issue 2, Pages (August 2018)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 71, Issue 2, Pages (February 2017)
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians)  Carsten Nieder, Thomas A.
Volume 52, Issue 6, Pages (December 2007)
Volume 55, Issue 6, Pages (June 2009)
Volume 71, Issue 5, Pages (May 2017)
Volume 67, Issue 6, Pages (June 2015)
Volume 49, Issue 4, Pages (April 2006)
Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy  Matthew Mossanen, Kenneth.
Volume 70, Issue 6, Pages (December 2016)
Volume 74, Issue 3, Pages (September 2018)
Volume 70, Issue 1, Pages (July 2016)
Volume 71, Issue 4, Pages (April 2017)
Volume 68, Issue 5, Pages (November 2015)
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary.
Volume 69, Issue 5, Pages (May 2016)
European Urology Oncology
Axel Heidenreich  European Urology Supplements 
Volume 52, Issue 4, Pages (October 2007)
European Urology Oncology
Axel Heidenreich  European Urology Supplements 
European Urology Oncology
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer  Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.
Presentation transcript:

Volume 68, Issue 4, Pages 570-577 (October 2015) Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration- resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302  Fred Saad, Neal Shore, Hendrik Van Poppel, Dana E. Rathkopf, Matthew R. Smith, Johann S. de Bono, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Peter F.A. Mulders, Paul Mainwaring, John D. Hainsworth, Tomasz M. Beer, Scott North, Yves Fradet, Thomas A. Griffin, Peter De Porre, Anil Londhe, Thian Kheoh, Eric J. Small, Howard I. Scher, Arturo Molina, Charles J. Ryan  European Urology  Volume 68, Issue 4, Pages 570-577 (October 2015) DOI: 10.1016/j.eururo.2015.04.032 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier estimates of (A) overall survival, (B) time to opiate use for cancer-related pain, and (C) time to deterioration in Eastern Cooperative Oncology Group performance status (ECOG PS) score by ≥1 point. AA=abiraterone acetate; BTT=bone-targeted therapy; CI=confidence interval; NE=not estimable; P=prednisone. European Urology 2015 68, 570-577DOI: (10.1016/j.eururo.2015.04.032) Copyright © 2015 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.